108 related articles for article (PubMed ID: 34279805)
1. Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.
Snyder S; Albertson T; Garcia J; Gitlin M; Jun MP
Adv Ther; 2021 Aug; 38(8):4541-4555. PubMed ID: 34279805
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers.
Ahmed N; Sun F; Teigland C; Kilgore KM; Mohammadi I; Chambers J; Dieyi C; Feng C; Osborn J; Fu C; Gergis U
Transplant Cell Ther; 2024 Apr; ():. PubMed ID: 38697294
[TBL] [Abstract][Full Text] [Related]
3. Geographic and Racial Disparities in Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma.
Shahzad M; Khalid MF; Amin MK; Basharat A; Ammad-Ud-Din M; Park R; Anwar I; Faisal MS; Jaglal M
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):316-322. PubMed ID: 38342727
[TBL] [Abstract][Full Text] [Related]
4. Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design.
Fyfe R; Anstis O; Kapadia K; Jordan M; Sword DO; Weinkove R
BMJ Open; 2024 Jan; 14(1):e071112. PubMed ID: 38262637
[TBL] [Abstract][Full Text] [Related]
5. Oncology nurse competency in chimeric antigen receptor T-cell therapy: A qualitative study.
He J; Li J; Feng LN; Feng LX; Qiang W; Wang W; Dong L
Nurse Educ Today; 2024 Jan; 132():106040. PubMed ID: 37956569
[TBL] [Abstract][Full Text] [Related]
6. Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy.
Wilson M; Thavorn K; Hawrysh T; Graham ID; Atkins H; Kekre N; Coyle D; Lalu MM; Fergusson DA; Chan KK; Ollendorf DA; Presseau J
BMJ Open; 2021 Aug; 11(8):e046707. PubMed ID: 34385243
[TBL] [Abstract][Full Text] [Related]
7. Assessing Medicaid Coverage for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy: A Project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS Initiative.
Auletta JJ; Khera N; DeMartino P; Kelkar AH; Yusuf RA; Davies SM; Knutson J; Beaver E; Maloney A; Majhail NS
Transplant Cell Ther; 2023 Nov; 29(11):713-720. PubMed ID: 37579920
[TBL] [Abstract][Full Text] [Related]
8. Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study.
Cavallo MC; Cavazza M; Bonifazi F; Casadei B; Cutini I; Tonietti B; Saccardi R; Zinzani P; Jommi C
BMC Health Serv Res; 2024 Jan; 24(1):121. PubMed ID: 38254079
[TBL] [Abstract][Full Text] [Related]
9. Modelling Potential Geographical Access of the Population to Public Hospitals and Quality Health Care in Romania.
Dumitrache L; Nae M; Simion G; Taloș AM
Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33207761
[TBL] [Abstract][Full Text] [Related]
10. Travel burdens to access care among children with cancer between 2016 and 2019: Analysis of a national population-based cancer registry in Japan.
Tsutsui A; Murakami Y; Okamura S; Fujimaki T; Endo M; Ohno Y
PLoS One; 2024; 19(4):e0300840. PubMed ID: 38625911
[TBL] [Abstract][Full Text] [Related]
11. The impact of transportation mode, socioeconomic deprivation and rurality on travel times to radiotherapy and surgical services for patients with prostate cancer: A national population-based evaluation.
Han L; Sullivan R; Tree A; Lewis D; Price P; Sangar V; van der Meulen J; Aggarwal A
Radiother Oncol; 2024 Mar; 192():110092. PubMed ID: 38219910
[TBL] [Abstract][Full Text] [Related]
12. Mediport use as an acceptable standard for CAR T cell infusion.
Eylon M; Prabhu S; John S; King MJM; Bhatt D; Curran KJ; Erickson C; Karras NA; Phillips CL; Satwani P; Hermiston M; Southworth E; Baumeister SHC; Talano JA; MacMillan ML; Rossoff J; Bonifant CL; Myers GD; Rouce RH; Toner K; Driscoll TA; Katsanis E; Salzberg DB; Schiff D; De Oliveira SN; Capitini CM; Pacenta HL; Pfeiffer T; Shah NC; Huynh V; Skiles JL; Fraint E; McNerney KO; Quigg TC; Krueger J; Ligon JA; Fabrizio VA; Baggott C; Laetsch TW; Schultz LM
Front Immunol; 2023; 14():1239132. PubMed ID: 37965315
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review.
Hansen DK; Liu YH; Ranjan S; Bhandari H; Potluri R; McFarland L; De Braganca KC; Huo S
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136292
[TBL] [Abstract][Full Text] [Related]
14. ACT To Sustain: Adoptive Cell Therapy To Sustain access to non-commercialized genetically modified cell therapies.
Gardner RA; White C; Elsallab M; Farnia S; Fraint E; Grilley B; Bateman-House A; Grupp SA; Kenderian S; Locke FL; Nikiforow S; Oluwole OO; Rouce RH; Spiegel J; Shah NN; Sharma A; Komanduri K; Gill S
Transplant Cell Ther; 2024 May; ():. PubMed ID: 38762057
[TBL] [Abstract][Full Text] [Related]
15. Development of a comprehensive measure of spatial access to HIV provider services, with application to Atlanta, Georgia.
Dasgupta S; Kramer MR; Rosenberg ES; Sanchez TH; Sullivan PS
Springerplus; 2016; 5(1):984. PubMed ID: 27429893
[TBL] [Abstract][Full Text] [Related]
16. [Organizational and budgetary impacts of the implementation of CAR-T cell therapies in a French academic hospital].
Fleta L; Gauthier M; Lider P; Campidelli A; Demoré B; Bensoussan D; Reppel L
Bull Cancer; 2023 Dec; 110(12):1260-1271. PubMed ID: 37679208
[TBL] [Abstract][Full Text] [Related]
17. Challenges in Global Access to CAR-T cells: an Asian Perspective.
Hwang WY; Takahashi S; Choi B; Huang H; Kawamata S; Ng SC; Gupta P; Hamidieh AA; Koaykul C; Irawan C; Srivastava A
Blood Cell Ther; 2024 Feb; 7(1):10-13. PubMed ID: 38486827
[TBL] [Abstract][Full Text] [Related]
18. Travel times to hospitals in Australia.
Barbieri S; Jorm L
Sci Data; 2019 Nov; 6(1):248. PubMed ID: 31676758
[TBL] [Abstract][Full Text] [Related]
19. Trends of travel burdens to access cancer care among children with cancer: analysis of a population-based cancer registry data in Aichi, Japan.
Tsutsui A; Ando N; Taniyama Y; Fujimaki T; Kawaura M; Matsuo K; Ito H; Ohno Y
Nagoya J Med Sci; 2023 Aug; 85(3):542-554. PubMed ID: 37829484
[TBL] [Abstract][Full Text] [Related]
20. Cancer Treatment Closer to the Patient Reduces Travel Burden, Time Toxicity, and Improves Patient Satisfaction, Results of 546 Consecutive Patients in a Northern Italian District.
Cavanna L; Citterio C; Mordenti P; Proietto M; Bosi C; Vecchia S
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138224
[No Abstract] [Full Text] [Related]
[Next] [New Search]
